RxDoctor Payments Data

Gordon Wotton, MD

Internal Medicine · Atlanta, GANPI 1952358012

Payments from drug & device makers

$18,437in general payments, 2019–2025

Across 1,035 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Lilly USA, LLC$2K
  • Amgen$2K
  • Sanofi-aventis U.S. LLC$1K
  • IBSA Pharma Inc.$876
  • Corcept Therapeutics$806
  • plus $9K from 49 others

What the payments were for

  • Speaking & faculty fees$720%
  • Food & beverage$18,27699%
  • Education$300%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,437 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$264,411
Medicare patients
418
Services billed
7,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide286$382,900
JardianceEmpagliflozin170$183,517
MounjaroTirzepatide127$145,569
Somatuline DepotLanreotide Acetate13$122,243
Tresiba Flextouch U-100Insulin Degludec146$107,572
FarxigaDapagliflozin Propanediol107$102,996
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog130$100,836
Tresiba Flextouch U-200Insulin Degludec54$85,252
ProliaDenosumab34$58,489
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog35$48,096
SynthroidLevothyroxine Sodium411$43,653
Fiasp FlextouchInsulin Aspart (Niacinamide)35$33,355
JanuviaSitagliptin Phosphate24$29,368
Novolog FlexpenInsulin Aspart64$20,935
TrulicityDulaglutide12$16,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$2,638$398,868313 claims
Boehringer IngelheimJardiance, Synjardy$703$200,076189 claims
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$2,218$163,057151 claims
Ipsen Biopharmaceuticals, IncSomatuline Depot$249$122,24313 claims
AstraZenecaFarxiga$600$102,996107 claims
AmgenProlia$1,817$58,48934 claims
AbbVieSynthroid$612$43,653411 claims
MerckJanuvia$379$29,36824 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$746$4,894392 claims
PfizerLevoxyl$18$20211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →